$Mainz Biomed(MYNZ.US)$ Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting Mainz Biomed will present its largest colorectal cancer screening study to date at the ASCO 2024 Annual Meeting. The study, combining data from ColoFuture and eAArly DETECT studies, includes 690 subjects across 30 clinical sites. The novel screening test, which uses mRNA biomarkers, FIT tests, and an AI algorithm, showed a 92.3% sensitivity for c...
Mainz Biomed股票討論區
美因茨比奧美德在 ASCO 2024 年度展示其集合研究的業界領先結果
美因茨 Biomed 在 ASCO 2024 年會上展示了他們最大的同組研究的結果。該研究涉及來自歐洲和美國 30 個專業腸胃科中心的 690 名臨床試驗,證實了他們對大腸癌(CRC)和晚期腺瘤(AA)的多模式篩查測試的高敏感度和特異性。該測試整合了糞便免疫化學 T...
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
Mainz Biomed will present its largest colorectal cancer screening study to date at the ASCO 2024 Annual Meeting. The study, combining data from ColoFuture and eAArly DETECT studies, includes 690 subjects across 30 clinical sites. The novel screening test, which uses mRNA biomarkers, FIT tests, and an AI algorithm, showed a 92.3% sensitivity for c...
新聞
美因茨 Biomed 在消化系統疾病周獲頒「傑出海報」,引領公司進行計劃的 FDA 試驗
美因茨 Biomed 在 2024 年消化疾病週(DDW)公布了突破性的 eAarly DETECT 研究結果,獲得了傑出海報獎。該研究表明對大腸癌(CRC)的敏感度為 97%,對晚期癌前病變的 82% 敏感度,高級不良症患者發現 100%。在美國多個站點進行,有 2 個...
新聞
美因茨 Biomed 將在華盛頓特區 2024 年消化疾病周上展示大腸直腸癌篩查研究的結果
暫無評論